Liposomal Amphotericin B Injectable Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 50 mg/vial
Reference Brands: AmBisome(US & EU)
Category: Anti-fungal
Liposomal Amphotericin B binds to fungal ergosterol, creating pores that disrupt cell membrane integrity and cause fungal cell death. It offers broad-spectrum activity, enhanced tissue penetration, and reduced toxicity compared to conventional formulations. Benefits include effective treatment of severe systemic infections with fewer side effects, improving patient outcomes. Liposomal Amphotericin B Injectable is available in Injection and strengths such as 50 mg/vial. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Liposomal Amphotericin B Injectable is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Liposomal Amphotericin B Injectable can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Liposomal Amphotericin B is approved in the EU and US for severe fungal infections. In the EU, Gilead’s AmBisome is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and high manufacturing standards. In the US, FDA-approved AmBisome is backed by comprehensive clinical data, biosimilarity assessments, and pharmacovigilance. Both regions require detailed dossiers for initial approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and submissions, visit PharmaTradz. We facilitate efficient market access for Liposomal Amphotericin B, ensuring adherence to European and American standards for safe, effective antifungal therapy, reducing toxicity while maintaining efficacy in severe infections.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Liposomal Amphotericin B is used to treat severe systemic fungal infections, including invasive aspergillosis, cryptococcal meningitis, mucormycosis, and systemic candidiasis. The liposomal formulation allows targeted delivery, improved tolerability, and reduced kidney toxicity compared to conventional amphotericin B.
Liposomal Amphotericin B contains amphotericin B encapsulated within liposomes made of phospholipids and cholesterol. This lipid-based structure helps the drug circulate longer in the bloodstream and reduces toxicity while maintaining strong antifungal activity.
The main trade name is AmBisome, widely used in the USA, EU, UK, and global markets.
AmBisome is manufactured by Gilead Sciences. Several other GMP-certified pharmaceutical companies also produce generic liposomal amphotericin B in different regions.
The generic name is amphotericin B (liposomal).
The primary brand name is AmBisome.
Liposomal Amphotericin B is manufactured in Gilead’s regulated facilities in the USA and Europe, along with other approved global GMP manufacturers producing generic versions for international distribution.
Related Products
Naftifine Hydrochloride
Strength:
1 %, 2%
Form: Cream / Gel
Reference Brands: Naftin (USA), Xolafin (USA)
View Details
Sertaconazole Nitrate
Strength:
2 %
Form: Creams
Reference Brands: Ertaczo (USA), Zalain (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
